Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:public_company
|
| gptkbp:CEO |
gptkb:Haywood_Miller
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:CUSIP |
29089Q105
|
| gptkbp:foundedYear |
1998
|
| gptkbp:headquartersLocation |
gptkb:Gaithersburg,_Maryland,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
NYSE:EBS
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US29089Q1058
|
| gptkbp:marketCap |
varies
|
| gptkbp:notableProduct |
gptkb:BioThrax
gptkb:Narcan |
| gptkbp:numberOfEmployees |
approximately 2,000
|
| gptkbp:operates |
gptkb:Emergent_BioSolutions
|
| gptkbp:produces |
vaccines
therapeutics biodefense products |
| gptkbp:stockExchange |
gptkb:New_York_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:EBS
|
| gptkbp:website |
https://www.emergentbiosolutions.com/
|
| gptkbp:bfsParent |
gptkb:Emergent_BioSolutions
|
| gptkbp:bfsLayer |
5
|